Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces ...

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...

Researchers at Case Western Reserve University have discovered molecules that present the potential to drive the development ...

Tyr Pharma (ATYR) announced a publication demonstrating the mechanism of action for its lead therapeutic candidate, efzofitimod, in the ...

Peer-reviewed publication validates efzofitimod’s unique anti-inflammatory mechanism of action on macrophages through ...

An innovative new technique uses a novel DNA barcode system to track hundreds of RNA and protein molecules in single cells within thick biological samples, providing researchers with a full picture of ...

This new article published in Genes & Diseases highlights the critical role of tRNA-derived small RNAs (tsRNAs) in digestive ...

This new article published in Genes & Diseases highlights the critical role of tRNA-derived small RNAs (tsRNAs) in digestive ...

Most individuals diagnosed with a rare disease won’t live to become teenagers or adults. I knew what I had to do.

This new article published in Genes & Diseases highlights the critical role of tRNA-derived small RNAs (tsRNAs) in digestive ...

This film creatively illustrates the process of protein synthesis through dance, symbolizing the assembly of amino acids into proteins. It explains how genes encode instructions for amino acid ...

SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-cl ...